Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores provide a framework for evaluating stocks based on value, growth, and momentum [2] Zacks Style Scores Overview - Stocks are rated A, B, C, D, or F based on their value, growth, and momentum characteristics, with higher scores indicating better performance potential [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - Evaluates stocks based on projected and historical earnings, sales, and cash flow to identify sustainable growth opportunities [4] Momentum Score - Assesses stocks based on price trends and earnings outlook, helping investors capitalize on upward or downward movements [5] VGM Score - Combines all three Style Scores to provide a comprehensive rating, highlighting stocks with attractive value, growth, and momentum [6] Zacks Rank Integration - The Zacks Rank uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.93% since 1988 [7] - There can be over 800 stocks rated 1 or 2, making it essential to utilize Style Scores for better selection [8] Investment Strategy - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks but high Style Scores may still face downward price pressure due to negative earnings outlooks [10] Company Spotlight: Stryker (SYK) - Stryker is a leader in medical technology, generating approximately 60% of sales from MedSurg & Neurotechnology and 40% from Orthopaedics [11] - The company has a Zacks Rank of 3 (Hold) and a VGM Score of B, with a strong Momentum Style Score of A [12] - Recent upward revisions in earnings estimates indicate positive growth potential, with the Zacks Consensus Estimate for fiscal 2025 at $13.55 per share [12][13]

Core Insights - Stryker reported revenue of $6.02 billion for the quarter ended June 2025, reflecting an 11.1% increase year-over-year and a surprise of +1.09% over the Zacks Consensus Estimate of $5.96 billion [1] - The company's EPS for the quarter was $3.13, up from $2.81 in the same quarter last year, exceeding the consensus estimate of $3.06 by +2.29% [1] Financial Performance Metrics - Stryker's stock has returned -0.7% over the past month, while the Zacks S&P 500 composite increased by +2.3%, indicating underperformance relative to the broader market [3] - The company holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the market in the near term [3] Revenue Breakdown by Geography and Business - Orthopaedics - Hips in the United States generated $283 million, surpassing the estimated $279.15 million, with an 8.4% year-over-year increase [4] - Orthopaedics - Knees in the United States reported $460 million, slightly below the $462.74 million estimate, reflecting a 6.2% year-over-year increase [4] - International sales for Orthopaedics - Hips reached $183 million, exceeding the $181.41 million estimate, marking a 9.6% year-over-year increase [4] - Overall Orthopaedics sales totaled $2.25 billion, below the $2.29 billion estimate, showing a -2.3% year-over-year change [4] - MedSurg and Neurotechnology sales were $3.77 billion, exceeding the $3.68 billion estimate, with a significant year-over-year increase of +21% [4] - Orthopaedics - Knees generated $640 million, slightly below the $641.42 million estimate, with a 6.3% year-over-year increase [4] - MedSurg and Neurotechnology - Medical sales reached $990 million, surpassing the $985.69 million estimate, reflecting a +9% year-over-year change [4] - MedSurg and Neurotechnology - Endoscopy reported $899 million, exceeding the $835.42 million estimate, with a +17.1% year-over-year increase [4] - Orthopaedics - Hips generated $466 million, above the $457.77 million estimate, with an 8.9% year-over-year increase [4] - Orthopaedics - Other sales reached $183 million, below the $194.65 million estimate, but showing a significant year-over-year increase of +34.6% [4] - Orthopaedics - Trauma and Extremities reported $957 million, exceeding the $916.05 million estimate, with a +15% year-over-year increase [4]